A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 4, 5 or 6 Infection and Compensated Cirrhosis

Mise à jour : Il y a 4 ans
Référence : NCT02642432

Femme et Homme

Extrait

The purpose of this study is to assess the safety and efficacy of ABT-493/ABT-530 following 12 weeks of treatment in adults with chronic Hepatitis C Virus Infection genotype 1, 2, 4, 5 or 6 infection and compensated cirrhosis.


Critère d'inclusion

  • Hepatitis C Virus Infection ,Chronic hepatitis C ,Compensated Cirrhosis


Liens